Screener
Aura Biosciences, Inc. AURA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Aura Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216808
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $27,960 | $23,343 |
| General and administrative | 6,906 | 5,692 |
| Total operating expenses | 34,866 | 29,035 |
| Total operating loss | (34,866) | (29,035) |
| Other income (expense): | ||
| Interest income, including amortization and accretion income | 1,190 | 1,594 |
| Other income (expense) | 2 | (24) |
| Total other income | 1,192 | 1,570 |
Item 1. Financial Statements.
FAQ
- What is Aura Biosciences, Inc.'s operating income?
- Aura Biosciences, Inc. (AURA) reported operating income of -$34.87M in Q1 2026.
- How has Aura Biosciences, Inc.'s operating income changed year-over-year?
- Aura Biosciences, Inc.'s operating income decreased by 20.1% year-over-year, from -$29.04M to -$34.87M.
- What is the long-term trend for Aura Biosciences, Inc.'s operating income?
- Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s operating income has grown at a 33.7% compound annual growth rate (CAGR), from -$35.25M to -$112.79M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Aura Biosciences, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude